Announcements

We are pleased to announce that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

Richard DiMarchi Indiana University, USA	Prof. Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, USA. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame. Dr. DiMarchi is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humulin®, Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon and incretin physiology and pioneered the discovery of single-molecule multi-mechanism agonists for the treatment of diabetes and obesity. The central element to success has been the chemical vision and technology to install within single molecules simultaneous agonism at related G-protein coupled receptors, coupled to the counter-intuitive discovery that glucagon and GIP agonism could synergize the therapeutic efficacy of GLP-1. These peptides and their conceptual approach have transformed the management of excessive body weight to a condition comparable to how hypertension, adult-onset diabetes, and excess cholesterol are medicinally managed.
“Professor DiMarchi was recognized by the 2024 Tu Youyou Award Committee members as being an exceptional leader in the medicinal chemistry of peptides and proteins of natural origin, and as a pioneer in the field of chemical biotechnology. His very important discoveries have led to breakthroughs in new drugs related to the therapy of diabetes and obesity. He has been named as an inventor on a very large number of patents, and he has had initially a highly successful scientific and administrative career in industry, which was followed by over two decades in academia as a distinguished professor.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee
Rolf Müller Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany; Helmholtz Centre for Infections Research (HZI), Germany; Saarland University, Germany	Prof. Rolf Müller is the Founding and Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biotechnology at Saarland University, Germany. Having received his training from the University of Bonn, he held research positions at the University of Washington, USA, and Braunschweig University of Technology, Germany, prior to his appointment as professor to Saarland University. His laboratory has dedicated itself to the exploration of bacterial natural-product biosynthetic pathways for more than 20 years and has extensive experience in working with myxobacteria and other microbial producer strains. Starting from the isolation and characterization of new microorganisms, the scope of work includes microbiology-, biotechnology-, bioinformatics-, and chemistry-based approaches to exploit these isolates as sources of new drugs with a special focus on novel anti-infectives. Müller and his team apply a variety of state-of-the-art analytical methods and biological assays to perform biological and chemical characterizations of the identified compounds. Prof. Müller has received several awards, including the prestigious Gottfried Wilhelm Leibniz Prize, the PHOENIX Pharmacy Research Award, the DECHEMA Prize, and the Inhoffen Medal, as well as being an elected member of acatech, Leopoldina, and the German Academy of Sciences and Literature.
“The 2024 Tu Youyou Award Committee members were highly impressed by the truly outstanding past and ongoing contributions of Professor Müller in both microbial natural products isolation chemistry and in biosynthesis, as well as in the development of lead compounds for their potential in treating human diseases, through his global connections with various major funding agencies. He is also a dedicated teacher who has trained numerous graduate students and postdoctoral fellows, and he has lectured on his research in countries all over the world.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee

The achievements of Richard DiMarchi and Rolf Müller highlight the transformative impact of natural products chemistry and medicinal chemistry. We congratulate them and invite the global academic community and public to join us in celebrating their significant contributions.

2024 Award Committee
Committee Chair:

• Prof. Dr. A. Douglas Kinghorn, Ohio State University, USA.
  

Committee Members (listed in alphabetical order):

• Prof. Angelo Fontana, University of Naples “Federico II”, Italy;
• Prof. Binghe Wang, Georgia State University, USA;
• Dr. Diana Pinto, University of Aveiro, Portugal;
• Prof. Hideaki Kakeya, Kyoto University, Japan;
• Dr. RuAngelie Edrada-Ebel, University of Strathclyde, UK;
• Prof. Thomas Prisinzano, University of Kentucky, USA
• Prof. Wei Li, University of Tennessee Health Science Center, USA.

About the Tu Youyou Award:
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honor the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award honoring exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Conference: The 17th Academic Conference of the Chinese Pharmacological Society

Date: 22–26 July 2025

Location: Xiong An, China

MDPI will be attending the 17th Academic Conference of the Chinese Pharmacological Society as an exhibitor, which will be held from 22 to 26 July 2025. We welcome researchers from diverse backgrounds to attend and share their latest ideas with us.

The year 2025 marks the 40th anniversary of the establishment of the Chinese Pharmacological Society. We are pleased to attend the conference, which will systematically summarize the experience of the Chinese Pharmacological Society’s construction and development over the past 40 years. The 17th Academic Conference of the Chinese Pharmacological Society serves as an interdisciplinary forum for the prompt exchange of recent achievements, experiences, theories, technologies, and methods in China's pharmacology research domain, in addition to new drug development and related fields, The conference will promote the innovative development of China's pharmacology research and new drug development on a longer-term basis. Your participation will significantly contribute to the medical discourse and enhance the conference’s impact within the pharmacological field.

The following MDPI journals will be represented at the conference:

• Biomedicines;
• Future Pharmacology;
• Pharmacy;
• Immuno;
• Marine Drugs;
• Pharmaceutics;
• Pharmacoepidemiology;
• Vaccines;
• JPBI.

If you are planning to attend the above conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information about the conference, please visit the following website: https://mm.sciconf.cn/cn/web/index/29613?pc=1.

We are pleased to share that Pharmaceutics (ISSN: 1999-4923) was awarded an increased Impact Factor of 5.5 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Pharmaceutics ranks in Q1 (34 among 352, Top 10%) in the JCR category of the “Pharmacology and Pharmacy” category.

The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years.

To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information.

The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.

We are pleased to share that Pharmaceutics (ISSN: 1999-4923) has received an updated CiteScore of 10.0 in June 2025. The CiteScore ranks the journal 22nd out of 185 titles (Q1) in the “Pharmaceutical Science” category, an impressive achievement for a journal running in Volume 17.

You can find more statistics on https://www.mdpi.com/journal/pharmaceutics/stats. 

The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance. 

This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Pharmaceutics and its growing impact in pharmaceutical formulation, process development, drug delivery, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research involving, but not limited to, engineering, biomedical sciences, and cell biology.

Pharmaceutical science is a dynamic and multidisciplinary field focused on the development, formulation, and manufacture of medicines and other pharmaceutical products. It encompasses a wide range of areas, including drug discovery and development, analytical methods, quality control, pharmacology, toxicology, and drug delivery systems. By integrating expertise across research and development, quality assurance, validation, and manufacturing, pharmaceutical science seeks to address critical challenges in medicine and improve health outcomes worldwide.

MDPI’s pharmaceutical science cluster serves as a vibrant hub for cutting-edge research, fostering a deep and comprehensive understanding of the vital role pharmaceuticals play in modern healthcare. Our mission goes beyond publishing; we aim to accelerate the dissemination of discoveries that drive innovation in drug development and pharmaceutical research. This cluster offers authors a variety of publishing opportunities, ensuring that the work of academics reaches the most relevant audiences and generates the greatest impact within the diverse landscape of pharmaceutical science.

Journal Cluster Overview

Journals	Launch Year	Impact Factor (2023)	CiteScore	First Decision (median)	Acceptance to Publication (median)	APC
	1933	2.3	4.6	26.1 Days	5.3 Days	CHF 1000
	2004	4.3	6.1	13.9 Days	3.4 Days	CHF 2900
	2009	4.9	7.9	15.5 Days	2.9 Days	CHF 2900
	2013	2.0	-	24.6 Days	3.3 Days	CHF 1800
	2021	-	-	19.2 Days	3.7 Days	CHF 1000
	2022	-	-	29.5 Days	4.7 Days	CHF 1000
	2022	-	-	25.7 Days	3.8 Days	CHF 1000
	2024	-	-	18 Days	4 Days	CHF 1000

MDPI’s Mission and Values:

As a pioneer of academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms across all disciplines. MDPI’s guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access: All of our content is published in open access and distributed under a Creative Commons License, providing free access to science and the latest research, allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency: Publishing the latest research through thorough editorial work, ensuring a first decision is provided to authors in under 32 days and papers are published within 7-10 days upon acceptance;
• Simplicity: Offering user-friendly tools and services in one place to enhance the efficiency of our editorial process;
• High-Quality Service: Supporting scholars and their work by providing a range of options such as journal publication at mdpi.com, early publication at preprints.org, and conferences on sciforum.net to make a positive impact on research;
• Flexibility: Adapting and developing new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability: Ensuring the long-term preservation of published papers and supporting the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open science practices.

Selected Topics and Special Issues:

• “Peptoids and Peptide Based Drugs”;
• “Research in Pharmacological Therapies, 2nd Edition”;
• “Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development”;
• “Natural Products and Drug Discovery—2nd Edition”;
• “Fighting SARS-CoV-2 and Related Viruses“;
• “Feature Papers to Celebrate the Inaugural Issue of Journal of Pharmaceutical and BioTech Industry”;
• “Feature Papers of Pharmacoepidemiology”.

The “Nanomedicine and Nanotechnology” Section of Pharmaceutics (ISSN: 1999-4923) publishes pioneering research in the broad field of nanomedicine. We take a holistic approach and encourage multidisciplinarity to understand new developments in nanotechnology and its applications in pharmaceutical, clinical, and diagnostic fields.

As all of the articles published in our journal are in open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly cited papers published in 2023, which are listed below.

1. “Chitosan: A Potential Biopolymer in Drug Delivery and Biomedical Applications”
by Nimeet Desai, Dhwani Rana, Sagar Salave, Raghav Gupta, Pranav Patel, Bharathi Karunakaran, Amit Sharma, Jyotsnendu Giri, Derajram Benival and Nagavendra Kommineni
Pharmaceutics 2023, 15(4), 1313; https://doi.org/10.3390/pharmaceutics15041313
Available online: https://www.mdpi.com/1999-4923/15/4/1313

2. “Superparamagnetic Iron Oxide Nanoparticles (SPION): From Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy”
by Thomas Vangijzegem, Valentin Lecomte, Indiana Ternad, Levy Van Leuven, Robert N Muller, Dimitri Stanicki and Sophie Laurent
Pharmaceutics 2023, 15(1), 236; https://doi.org/10.3390/pharmaceutics15010236
Available online: https://www.mdpi.com/1999-4923/15/1/236

3. “Antimicrobial Nano-Zinc Oxide Biocomposites for Wound Healing Applications: A Review”
by Paolo Pino, Francesca Bosco, Chiara Mollea and Barbara Onida
Pharmaceutics 2023, 15(3), 970; https://doi.org/10.3390/pharmaceutics15030970
Available online: https://www.mdpi.com/1999-4923/15/3/970

4. “Cationic Polymers as Transfection Reagents for Nucleic Acid Delivery”
by Xiaomeng Cai, Rui Dou, Chen Guo, Jiaruo Tang, Xiajuan Li, Jun Chen and Jiayu Zhang
Pharmaceutics 2023, 15(5), 1502; https://doi.org/10.3390/pharmaceutics15051502
Available online: https://www.mdpi.com/1999-4923/15/5/1502

5. “Carbon Dots: Opportunities and Challenges in Cancer Therapy”
by Tanima Bhattacharya, Gye Hwa Shin and Jun Tae Kim
Pharmaceutics 2023, 15(3), 1019; https://doi.org/10.3390/pharmaceutics15031019
Available online: https://www.mdpi.com/1999-4923/15/3/1019

6. “ZnO@ZIF-8 Nanoparticles as Nanocarrier of Ciprofloxacin for Antimicrobial Activity”
by Bruno Altran Costa, Marina Paiva Abuçafy, Thúlio Wliandon Lemos Barbosa, Bruna Lallo da Silva, Rafael Bianchini Fulindi, Guilherme Isquibola, Paulo Inácio da Costa and Leila Aparecida Chiavacci
Pharmaceutics 2023, 15(1), 259; https://doi.org/10.3390/pharmaceutics15010259
Available online: https://www.mdpi.com/1999-4923/15/1/259

7. “Biocompatible Calcium Ion-Doped Magnesium Ferrite Nanoparticles as a New Family of Photothermal Therapeutic Materials for Cancer Treatment”
by Panchanathan Manivasagan, Sekar Ashokkumar, Ala Manohar, Ara Joe, Hyo-Won Han, Sun-Hwa Seo, Thavasyappan Thambi, Hai-Sang Duong, Nagendra Kumar Kaushik, Ki Hyeon Kim et al.
Pharmaceutics 2023, 15(5), 1555; https://doi.org/10.3390/pharmaceutics15051555
Available online: https://www.mdpi.com/1999-4923/15/5/1555

8. “Screening Libraries to Discover Molecular Design Principles for the Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers Derived from Plant Phenolic Acids”
by Juncheng Lu, Elena N. Atochina-Vasserman, Devendra S. Maurya, Muhammad Irhash Shalihin, Dapeng Zhang, Srijay S. Chenna, Jasper Adamson, Matthew Liu, Habib Ur Rehman Shah, Honey Shah et al.
Pharmaceutics 2023, 15(6), 1572; https://doi.org/10.3390/pharmaceutics15061572
Available online: https://www.mdpi.com/1999-4923/15/6/1572

9. “Increasing Bioavailability of Trans-Ferulic Acid by Encapsulation in Functionalized Mesoporous Silica”
by Gabriela Petrișor, Ludmila Motelica, Denisa Ficai, Cornelia-Ioana Ilie, Roxana Doina Trușcǎ, Vasile-Adrian Surdu, Ovidiu-Cristian Oprea, Andreea-Luiza Mȋrț, Gabriel Vasilievici, Augustin Semenescu et al.
Pharmaceutics 2023, 15(2), 660; https://doi.org/10.3390/pharmaceutics15020660
Available online:  https://www.mdpi.com/1999-4923/15/2/660

10. “Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment”
by Vineela Parvathaneni, Snehal K Shukla and Vivek Gupta
Pharmaceutics 2023, 15(3), 1001; https://doi.org/10.3390/pharmaceutics15031001
Available online:  https://www.mdpi.com/1999-4923/15/3/1001

MDPI is excited to collaborate with Toronto Metropolitan University to host an engaging Scientific Publishing Workshop aimed at empowering scholars with the knowledge and tools needed to succeed in academic publishing. This workshop will delve into the key aspects of MDPI’s open access publishing framework, offering an in-depth exploration of journal selection, the editorial workflow, and the essentials of publication ethics. Participants will also gain practical advice on improving their scientific writing and effectively addressing reviewer comments, with guidance from an experienced professional. This session promises to equip attendees with valuable skills to elevate their publishing journey.

Workshop Highlights:

• Learn How to Better Write and Structure a Research Article;
• How to Choose Where to Publish Academic Work;
• How to Respond to Reviewer Comments;
• Reasons for Rejection During Pre-Check;
• How to Navigate Through Ethics and AI Use.

Date: 15 May 2025
Time: 12:00–1:30 p.m.
Venue: Toronto Metropolitan University

Program:

We are pleased to announce the winners of the Pharmaceutics Outstanding Reviewer Award: Dr. Dinesh Nyavanandi, Dr. Zhengwei Huang and Dr. Mladena Lalić-Popović.

Name: Dr. Dinesh Nyavanandi

Affiliation: Research Scientist Drug Product Design & Development, USA

Research interests: solid oral dosage forms; amorphous solid dispersions; solubility enhancement; hot melt extrusion; FDM 3D printing; twin-screw granulation; high-shear granulation; tableting; encapsulation; spray drying; roller compaction; lipid-based formulation

Below is a short interview with one of the winners, Dr. Dinesh Nyavanandi.

1. Could you introduce yourself to our readers? What is your current research area?

I am Dinesh Nyavanandi, currently working as a research scientist in small molecule drug product development at AbbVie, with over four years of industrial experience. I earned my Ph.D. in pharmaceutics and drug delivery from the University of Mississippi, where my research focused on exploring novel applications of hot melt extrusion (HME)—both as a standalone technique, such as twin-screw granulation, and in combination with additive manufacturing methods like fused deposition modeling (FDM).

My research interests include advanced manufacturing platforms, continuous processing, solubility enhancement strategies, and tackling stability-related challenges to address unmet needs in oral drug delivery.

2. Which research topics do you think will be of particular interest to the research community in the coming years?

In the coming years, I believe the research community will place strong emphasis on advanced manufacturing technologies that enable precision, scalability, and sustainability in drug product development. Key areas of interest include:

• Continuous Manufacturing;
• Additive Manufacturing (3D Printing);
• Solubility and Bioavailability Enhancement;
• Formulation for Emerging Modalities;
• Digital and AI-Driven Formulation Design;
• Green and Sustainable Pharma;
• Early Development Strategies for Speed-to-Clinic.

3. What factors motivate you to be a reviewer for Pharmaceutics?

As a formulation scientist with a strong academic foundation and industry experience in small molecule drug product development, I am deeply committed to the advancement of pharmaceutical sciences. Serving as a reviewer for Pharmaceutics allows me to stay current with cutting-edge research, particularly in areas aligned with my expertise—such as hot melt extrusion, continuous manufacturing, and solubility enhancement strategies.

Reviewing also gives me an opportunity to contribute to the scientific community by supporting the publication of high-quality, rigorous research. It sharpens my critical thinking, fosters professional growth, and offers a meaningful way to give back by helping authors improve their work through constructive feedback.

Ultimately, I see peer review as both a responsibility and a privilege—one that helps uphold the integrity of scientific literature while reinforcing my own commitment to research excellence.

4. Could you please share with us your experience as a reviewer for Pharmaceutics?

Serving as a reviewer for Pharmaceutics has been a highly rewarding and intellectually stimulating experience. It has allowed me to critically engage with cutting-edge research in areas closely aligned with my expertise, including solid oral dosage forms, hot melt extrusion, additive manufacturing, and enabling technologies for poorly soluble drugs.

Through the peer review process, I have had the opportunity to evaluate manuscripts spanning a wide range of formulation and drug delivery strategies. I strive to provide detailed, constructive, and fair feedback that not only assesses scientific merit but also supports authors in improving the clarity, rigor, and impact of their work.

This role has also helped me stay abreast of the latest advancements in the field, sharpen my critical thinking skills, and contribute to maintaining the scientific quality and integrity of published literature. I view peer reviewing not just as a professional duty, but as an integral part of my contribution to the global pharmaceutical sciences community.

5. What are the key factors and aspects that you consider most when reviewing a manuscript?

When reviewing a manuscript, I focus on several critical aspects to ensure the work meets the standards of scientific rigor, novelty, and relevance:

• Scientific Merit and Originality;
• Relevance to the Journal and Field;
• Experimental Design and Methodology;
• Data Quality and Interpretation;
• Clarity and Organization;
• Ethical Standards and Transparency;
• Impact and Applicability.

6. What are your opinions about the scientific publication market, and what do you think about the open access model?

From my perspective, open access:

• Fosters greater visibility and impact of published work, often leading to wider readership and more citations;
• Promotes collaboration and knowledge sharing across regions and disciplines;
• Aligns with the mission of scientific advancement, ensuring that publicly funded research is accessible to the public and stakeholders.

7. As the winner of this award, would you like to take a moment to share your thoughts with our readers or express gratitude towards those who have played a significant role in your research accomplishments?

I am truly honored and grateful to receive this recognition. This award is not only a validation of my research journey but also a reflection of the incredible support, mentorship, and collaboration I have been fortunate to experience.

I would like to express my heartfelt gratitude to Dr. Michael A. Repka, my Ph.D. advisor at the University of Mississippi, whose mentorship played a pivotal role in shaping my scientific thinking and research direction. His unwavering support and encouragement allowed me to explore innovative approaches in drug delivery and advanced manufacturing, which continue to inspire my work today.

I also extend my thanks to my colleagues, collaborators, and peers—both in academia and industry—whose shared passion for pharmaceutical science has enriched my professional journey. Finally, I am deeply appreciative of my family and friends, whose constant support keeps me grounded and motivated.

This recognition energizes me to continue contributing to the field, and I hope to inspire future scientists the same way I have been inspired throughout my career.

We are pleased to announce the winners of the Pharmaceutics Outstanding Reviewer Award: Dr. Dinesh Nyavanandi, Dr. Zhengwei Huang and Dr. Mladena Lalić-Popović.

Name: Dr. Mladena Lalić-Popović

Affiliation: University of Novi Sad, Serbia

Research interests: pharmaceutical technology; solid dispersion; ASD; compounding; formulation development; drug permeability

Below is a short interview with one of the winners, Dr. Mladena Lalić-Popović.

1. Could you introduce yourself to our readers? What is your current research area?

My name is Mladena Lalić-Popović. I am a full professor teaching pharmaceutical technology and pharmaceutical practice within the broader scientific field of pharmaceutical technology, industrial pharmacy, and cosmetology at the Department of Pharmacy, Faculty of Medicine, University of Novi Sad. I am a healthcare specialist in the field of pharmaceutical technology and am involved with the Center for Medical and Pharmaceutical Investigations and Quality Control (CEMPhIC).

2. Which research topics do you think will be of particular interest to the research community in the coming years?

I believe that science is increasingly focused on applicability. We face great challenges, especially in medicine and pharmacy. Research aimed at improving the utilization of existing drugs is important from clinical, ecological, and economic perspectives. Technological solutions that enable the effective and safe use of drugs are crucial not only from a scientific standpoint but also from the perspective of the pharmaceutical industry. In this regard, research into modern pharmaceutical forms such as 3D-printed and nanodrugs will be the focus of scientific investigations in the coming years.

3. What factors motivate you to be a reviewer for Pharmaceutics?

Pharmaceutics is a pertinent journal in the field to which I belong. I believe that MDPI has developed one of the most efficient systems currently, appropriate for authors, scientific audiences, and reviewers. I am always impressed by the speed of the entire process and the quality of the published papers. It is a pleasure to collaborate with journals such as Pharmaceutics.

4. Could you please share with us your experience as a reviewer for Pharmaceutics?

During the review process, I had the opportunity to stay updated on current developments in the field of pharmaceutics. Pharmaceutics receives a significant number of high-quality and up-to-date papers, addressing topics of great scientific importance using contemporary scientific methods. The respect for my decisions in the subsequent decision-making process concerning the publication of papers is of special significance.

5. What are the key factors and aspects that you consider most when reviewing a manuscript?

First, I look for originality and then novelty. The manuscript should be well-organized and easy to follow in terms of the research. The aim should be clearly defined, and the methodology should be presented in a way that logically supports the achievement of the aim.

6. What are your opinions about the scientific publication market, and what do you think about the open access model?

The economic aspects of publishing papers are undoubtedly a challenging circumstance for every researcher. Paying for paper publication is as difficult as paying for access to information from other colleagues. For these reasons, I believe the MDPI system is fair and fosters competitiveness of researchers who lack financial and institutional support.

Any success should be supported by a team. Human resources are the most important part of scientific research. The transfer of knowledge and experience is essential for the improvement of individuals. I am deeply grateful to all my mentors, professors, and colleagues who have contributed to my undergraduate and postgraduate education, as well as to my scientific collaborations.